Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)

by R.E. Coleman, M. Collinson, W. Gregory, H. Marshall, R. Bell, D. Dodwell, M. Keane, M. Gil, P. Barrett-Lee, D. Ritchie, A. Bowman, V. Liversedge, R.H. De Boer, J.L. Passos-Coelho, S. O'Reilly, G. Bertelli, J. Joffe, J.E. Brown, C. Wilson, J.C. Tercero, J. Jean-Mairet, R. Gomis, D. Cameron
Published 2018-11-01